

This is a repository copy of *Inclusivity of the target population in orthopaedic surgical randomised trials:a review of high impact journals.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/225628/>

Version: Published Version

Article:

Brealey, Stephen Derek orcid.org/0000-0001-9749-7014, Atha, Lucy orcid.org/0000-0003-3495-6468, Knowlson, Catherine et al. (8 more authors) (2025) Inclusivity of the target population in orthopaedic surgical randomised trials:a review of high impact journals. NIHR Open Research. 6. ISSN 2633-4402

<https://doi.org/10.3310/nihropenres.13781.2>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.






Check for updates

RESEARCH ARTICLE

REVISED Inclusivity of the target population in orthopaedic surgical randomised trials: a review of high impact journals

[version 2; peer review: 1 approved with reservations, 1 not approved]

Stephen D Brealey ¹, Lucy Atha¹, Catherine Knowlson¹, Elizabeth Cook¹, Kate Hicks¹, Joanne Newman¹, Arabella Scantlebury¹, Joy Adamson¹, Caroline Fairhurst ¹, Nick A Johnson^{1,2}, Joseph J Dias ²

¹Department of Health Sciences, York Trials Unit, University of York, York, England, UK

²University Hospitals of Leicester NHS Trust, Leicester, UK

V2 First published: 24 Jan 2025, 5:6
<https://doi.org/10.3310/nihropenres.13781.1>
Latest published: 03 Apr 2025, 5:6
<https://doi.org/10.3310/nihropenres.13781.2>

Abstract

Background

This review examines whether randomised controlled trials (RCTs) of surgery in orthopaedics are inclusive of their target populations, including under-served populations.

Methods

The BMJ, Journal of the American Medical Association, The Lancet, and The New England Journal of Medicine were electronically searched in February 2022 for eligible RCTs published from 1 January 2014. Screening, key baseline patient characteristics, the inclusion of under-served groups and whether patient recruitment was pragmatic in design were key data extracted. The findings were tabulated and reported narratively.


Results

There were 26 RCTs included that were parallel in design and conducted across a range of countries in different hospital settings. Four RCTs did not report the complete CONSORT statement. There was variation in the percentage of the screened population who were randomised into the studies ranging from 5.8% to 74.7%. Most RCTs were pragmatic in design regarding patient selection but this did not necessarily translate to an inclusive trial population. Only two RCTs reported the age and gender of all screened patients. All 26 RCTs

Open Peer Review

Approval Status ? X

| | 1 | 2 |
|--|-----------|-----------|
| version 2 (revision) 03 Apr 2025 | | |
| version 1 24 Jan 2025 | ? view | X view |

1. Ameeta Retzer, University of Birmingham, Birmingham, UK
2. Kim Madden , McMaster University, Hamilton, Canada

Any reports and responses or comments on the article can be found at the end of the article.

reported the age and gender of randomised patients but only four studies reported ethnicity. Reporting about the consideration and inclusion of under-served populations was limited.

Conclusions

There is variation in the exclusion of patients of the target population. Reporting of key patient characteristics during screening and attention given to under-served populations in the design, conduct and reporting of these trials is limited. Training and education on inclusivity is required along with practical guidance about how to implement this. To improve inclusivity in the screening and recruitment of patients there should be a focus on (i) screening and eligibility criteria, (ii) collection and reporting on attributes to ensure no section of the eligible population is inadvertently excluded, and (iii) embedding mechanisms to allow all eligible patients the opportunity to participate.

Plain Language Summary

Orthopaedic surgical trials often aim to evaluate surgery in real-world settings, including a wide range of participants to reflect the target population. This approach helps ensure the research is relevant to clinical practice and that the findings can be widely applied. The National Institute for Health and Care Research (NIHR) in the United Kingdom is focusing on improving the inclusion of under-represented groups in healthcare research, such as those of different ages, educational backgrounds, and language abilities. Including diverse participants in trials is crucial to avoid missing important findings and to prevent discrimination. This review looked at whether orthopaedic surgical trials are inclusive of their target populations, including under-served groups. It included 26 trials from various countries and hospital settings. The review found that there is variation in how patients are excluded, limited reporting of key patient characteristics, and insufficient attention to under-served populations in the design and conduct of these trials. Training and education on inclusivity is required along with practical guidance about how to implement this. To make trials more inclusive and representative, there should be a focus on the following (i) the criteria for screening and eligibility, (ii) collecting and reporting information to ensure no eligible group is left out, and (iii) create ways for all eligible patients to participate.

Keywords

Inclusivity; Under-served; Orthopaedics; Surgery; Randomised trials; Review

Corresponding author: Stephen D Brealey (stephen.brealey@york.ac.uk)

Author roles: **Brealey SD:** Conceptualization, Data Curation, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Atha L:** Conceptualization, Data Curation, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Knowlson C:** Conceptualization, Data Curation, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Cook E:** Conceptualization, Data Curation, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Hicks K:** Conceptualization, Data Curation, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Newman J:** Conceptualization, Data Curation, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Scantlebury A:** Conceptualization, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Adamson J:** Conceptualization, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Fairhurst C:** Conceptualization, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Johnson NA:** Conceptualization, Data Curation, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Dias JJ:** Conceptualization, Data Curation, Investigation, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This project is funded by the National Institute for Health Research (NIHR) under its [‘Health Technology Assessment Programme’ (Grant Reference Number NIHR133418)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Copyright: © 2025 Brealey SD *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Brealey SD, Atha L, Knowlson C *et al.* **Inclusivity of the target population in orthopaedic surgical randomised trials: a review of high impact journals [version 2; peer review: 1 approved with reservations, 1 not approved]** NIHR Open Research 2025, 5:6 <https://doi.org/10.3310/nihropenres.13781.2>

First published: 24 Jan 2025, 5:6 <https://doi.org/10.3310/nihropenres.13781.1>

REVISED Amendments from Version 1

The reporting on place of residence for a study has been amended with reference to Table 6S. The fourth paragraph of the Discussion has had a sentence added that acknowledges the restrictions of data capture for different jurisdictions. The final paragraph of the Discussion has been updated to explain the focus on high impact journals, to acknowledge that different journals have different policies about what can be reported and uploaded with an article, and acknowledged the limitations of the search strategy.

Any further responses from the reviewers can be found at the end of the article

Introduction

Orthopaedic surgical randomised controlled trials (RCTs) are often pragmatically designed to evaluate whether surgery is an effective intervention in a realistic clinical setting^{1,2}. The evaluation of surgery, lends itself to a pragmatic approach, by its complex nature¹. A critical aim of a pragmatic approach is to be inclusive of a broad sample of participants that will reflect the target population in clinical practice and maximise the generalisability of findings.

Differences in recruitment across sites, however, is common in pragmatic RCTs³. This can result in recruited patients differing from those who are not recruited across characteristics such as age, sex, ethnicity, severity of disease, educational status, social class, and place of residence⁴. Reviews show that trials consistently fail to report participant flow accurately, particularly before informed consent and randomisation^{5,6}. As it is not always clear how many patients were screened for inclusion and why they were not randomised, the results may not be accepted by the surgical community. The National Institute for Health and Care Research (NIHR), the United Kingdom's (UK) largest public funder of trials, has begun to focus on the inclusion of under-represented groups in health care research. Various grouping have been suggested for consideration and include the following: demographic factors (e.g. age, sex, ethnicity); social and economic factors (e.g. employment, socio-economic status, geographic location, language, digitally excluded); and health status (e.g. mental health condition, cognitive impairment, physical disabilities)^{7,8}. Inclusivity in trials is important for improving representation of the target population so important findings specific to different populations are not missed and to avoid potential discrimination towards historically under-served populations. More money, time and effort may be required to be more inclusive, but may lend itself to research that is representative of the whole patient population and as a result, is more informative for patient and clinical decision-making⁸.

For orthopaedic surgical trials, the focus has been on improving internal validity^{1,9} rather than on their applicability to practice¹⁰. A criticism of such trials has been that the screening, choice, and application of eligibility criteria has meant many patients are excluded. This may affect whether clinicians accept the results of a trial if not considered to be reflective of their usual patients. Treatments may then not be used that could benefit patients and optimise the efficient use of NHS resources, or alternatively, are continued to be used when they have limited

clinical and/or cost-effectiveness. This lack of representation has been interpreted as limiting the applicability of the findings of orthopaedic surgical trials^{11,12} and can delay their translation into practice and increase research waste¹³.

In the absence of literature exploring the applicability of orthopaedic surgical trials, that such trials have been criticised for a lack of patient representation, and the emerging policy to be inclusive of underserved groups we judged it was timely to conduct a review on this topic. We chose to focus on orthopaedic trials that are published in high impact medical journals that are likely to have high visibility and potential to influence key stakeholders and clinical practice¹². The aim of this review of high impact journals was to examine whether published findings of RCTs of surgery in orthopaedics are inclusive of their target populations and suggest practical recommendations for encouraging inclusivity by design in future orthopaedic surgical trials.

Methods

Patient and Public Involvement

There was no Patient and Public involvement in this research.

We adapted systematic review methodology to robustly review current methodological practice in orthopaedic surgical trials. To optimise study design and transparency in our reporting the protocol and the findings are aligned with the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) checklist and the PRISMA guidance^{14,15}. The review was prospectively registered with Research on Research hub (<https://ror-hub.org/study/1955/>).

Eligibility criteria

Individually randomised trials that included an orthopaedic patient population defined as involving bone or joint disorders were eligible for inclusion. Trials must have included surgery compared with: other surgical intervention(s); non-operative (i.e. did not involve surgery) interventions; or a placebo-control. Surgery was defined as any interventional procedure that changes the anatomy and requires a skin incision or the use of endoscopic techniques; dental studies were excluded. Placebo refers to a surgical placebo, a sham surgery, or an imitation procedure intended to mimic the active intervention. This includes when a scope is inserted and nothing was done but patients were sedated or under general anaesthesia and could not distinguish whether or not they underwent the actual procedure¹⁶. RCTs could be conducted anywhere but only articles written in the English language were included.

Information sources and search strategy

The BMJ, Journal of the American Medical Association (JAMA), The Lancet, and The New England Journal of Medicine (NEJM) were chosen as examples of top-ranking medical journals and electronically searched in February 2022 for eligible RCTs published from 1 January 2014. That year was chosen as it is when concerns were raised about the DRAFFT trial and the number of patients excluded^{11,17}. For the BMJ, the date to filter from 01/01/2014 to 06/02/2022 (defaults to today's date) was selected, "Research" as the type of article and by "trial" in the title. For the Lancet, the publication range could be customised from January 2014 to February 2022. The

search terms “randomised” and “trial” were selected to be in the title of “The Lancet” journal and then results selected on Research Article. For JAMA, the search term used was “randomized clinical trial”, then for article type “research” was selected and for content type “article” with a customised date range of 1 January 2014 to 6 February 2022. Finally, for the NEJM, the term “randomized” was used to search within the abstract, “research” for article category and a date range of 2014/01/01 to 2022/02/28).

Study selection

One reviewer screened all titles and abstracts to identify potentially eligible studies. Full manuscripts of potentially relevant studies were assessed by the reviewer against the eligibility criteria and independently checked by a second reviewer (LA, CK, EC, KH, JN, JA). Disagreements over eligibility were resolved through discussion or recourse to a third reviewer (SB).

Data extraction

A data extraction form was developed in Microsoft Excel and piloted using six studies to assess eligibility and two studies for data extraction. Data collected from the piloting of the form was not included in the review. Data were extracted from the main publication and supplementary files by one reviewer and checked by a second reviewer (LA, CK, EC, KH, JN, JA). Disagreements over data extraction were resolved through discussion or recourse to a third reviewer (SB).

Data items

Information extracted included author, year, study design (e.g. parallel, factorial), country, setting (e.g. number of trauma hospitals/major trauma centres), target patient population (e.g. top level of the CONSORT¹⁸ statement flowchart or equivalent in text), eligibility criteria, recruitment period, intervention/comparator(s), number of patients (screened, excluded, not consented, randomised), reasons for exclusion, recruitment (i.e. where e.g. clinic, ward, intensive care units; how e.g. search medical databases, media advertising, use of incentives) and age (years), gender and ethnicity of patients.

Data extracted about under-served populations and patients being able to consent included: language barriers (e.g. translation, literacy); allowance for disability (e.g. visual/hearing impairment); electronic data collection (i.e. digital disadvantage); and lack of capacity to consent for themselves¹⁹.

Domains of the PRECIS-2 tool were used to rate whether recruitment of patients was pragmatic on a scale of 1 to 5 (i.e. very explanatory, rather explanatory, equally pragmatic and explanatory, rather pragmatic, very pragmatic) for eligibility, recruitment and setting²⁰. This was undertaken by one reviewer (NJ) and checked by a second reviewer (JD) and, if necessary, recourse to a third reviewer (SB).

Quality appraisal was not undertaken as it was not an effectiveness review.

Data synthesis

A narrative and tabular summary of key study characteristics is provided, including the target patient population and eligibility criteria.

The following numbers of patients are presented: (i) screened for enrolment; (ii) excluded based on eligibility criteria; (iii) did not consent; and (iv) randomised. These numbers are presented for all included trials and stratified by the type of comparator.

Age, gender and ethnicity of patients at baseline are summarised descriptively for (i) screened (entire sample); (ii) ineligible (excluded patients); (iii) non-consenting; and (iv) randomised patients. This is presented for all trials and stratified by the type of comparator.

A fixed effects meta-analysis to explore heterogeneity in baseline characteristics (i.e. age, gender, ethnicity) between patients screened but not randomised and those randomised using the I^2 statistic was planned²¹. This was not feasible as there were too few studies, nor for this reason was the planned subgroup analyses about how pragmatic was the trial design or type of comparator.

Finally, whether under-served patient populations were considered including facilitators to consent and whether the trials were pragmatic in the selection and recruitment of patients is tabulated.

Results

Study selection

3,030 potentially eligible studies were identified. After screening the title and abstract, there was full retrieval of journal articles for 27 studies; one was subsequently excluded that did not include surgery²². Therefore 26 studies were included^{17,23–47}. Figure 1 summarises the study selection process. Table 1S in the extended data gives a detailed description of the eligibility criteria and patient population.

Study characteristics

Table 2S summarises the study characteristics. All studies were parallel in design, four included a sham or placebo-control^{25,41,42,47}, and were conducted across a wide range of countries in different hospital settings. Nine studies did not clearly report where recruitment was undertaken^{17,23,24,32,34,36,37,39,47}; among those that did, recruitment took place in locations including out-patient clinics, fracture clinics, wards, and emergency departments. Twelve studies did not report how recruitment was conducted^{17,23,24,28,31,33,34,39–42,47}. For the remaining studies, recruitment included screening by trial co-ordinators/research associates, review by individual or expert panel of surgeons, or new admissions by surgical teams. The detailed eligibility criteria of the included trials are available in Figshare repository for which further details are in the Data Availability section.

Completion of the CONSORT statement

Table 1 describes the number of patients screened for enrolment, excluded, eligible, non-consenting and randomised as reported in the CONSORT flowchart. Four studies did not fully complete the reporting of patients in the study^{17,28,29,36}. There was variation in the percentage of the screened and eligible population who were randomised ranging from 5.8% up to 74.7% and 30.1% up to 92.4%, respectively. This occurred within studies of different comparators with the surgical intervention.




Figure 1. Flowchart of included studies.

Table 1. CONSORT statement flowchart.

| Author (year) | Surgery comparator | Number of patients screened | Number of patients excluded | Number of patients eligible | Number of patients not consenting | Number of patients randomised (% of screened & % of eligible) |
|------------------------------|----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------------|---|
| Rangan <i>et al.</i> , 2020 | Multiple comparators | 914 | 116 | 798 | 295 | 503 (55.0% & 63.0%) |
| Skou <i>et al.</i> , 2015 | Non-operative intervention | 1475 | 1348 | 127 | 27 | 100 (6.8% & 78.7%) |
| Bailey <i>et al.</i> , 2020 | Non-operative intervention | 790 | 622 | 168 | 40 | 128 (16.2% & 76.2%) |
| Willett <i>et al.</i> , 2016 | Non-operative intervention | 2015 | 1344 | 671 | 51 | 620 (30.8% & 92.4%) |
| Rangan <i>et al.</i> , 2015 | Non-operative intervention | 1250 | 687 | 563 | 313 | 250 (20.0% & 44.4%) |

| Author (year) | Surgery comparator | Number of patients screened | Number of patients excluded | Number of patients eligible | Number of patients not consenting | Number of patients randomised (% of screened & % of eligible) |
|-----------------------------------|----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------------|---|
| van de Graaf <i>et al.</i> , 2018 | Non-operative intervention | Not reported | Not reported | Not reported | Not reported | 321 |
| Rämö <i>et al.</i> , 2020 | Non-operative intervention | 321 | 181 | 140 | 58 | 82 (25.5% & 58.6%) |
| Costa <i>et al.</i> , 2022 | Non-operative intervention | 2636 | 1936 | 700 | 196 | 504 (19.1% & 72.0%) |
| Griffin <i>et al.</i> , 2014 | Non-operative intervention | 2006 | 1504 | 502 | 351 | 151 (7.5% & 30.1%) |
| Kise <i>et al.</i> , 2016 | Non-operative intervention | 341 | 115 | 226 | 85 | 140 ^a (41.0% & 61.9%) |
| Palmer <i>et al.</i> , 2019 | Non-operative intervention | 495 | 145 | 350 | 128 | 222 (44.8% & 63.4%) |
| Reijman <i>et al.</i> , 2021 | Non-operative intervention | Not reported | Not reported | 282 | 115 | 167 (N/A & 59.2%) |
| Dias <i>et al.</i> , 2020 | Non-operative intervention | 1047 | 272 | 775 | 336 | 439 (41.9% & 56.6%) |
| Griffin <i>et al.</i> , 2018 | Non-operative intervention | 6028 | 5380 | 648 | 268 ^b | 348 ^c (5.8% & 53.7%) |
| Ghogawala <i>et al.</i> , 2016 | Other surgery | Not reported | Not reported | 130 | 64 ^d | 66 (N/A & 50.8%) |
| Försth <i>et al.</i> , 2016 | Other surgery | 358 | 59 | 299 | 52 | 247 (69.0% & 82.6%) |
| Ghogawala <i>et al.</i> , 2021 | Other surgery | 458 | 168 | 290 | 127 ^e | 163 (35.6% & 56.2%) |
| Costa <i>et al.</i> , 2017 | Other surgery | 537 | 131 | 406 | 85 | 321 (59.8% & 79.1%) |
| Costa <i>et al.</i> , 2014 | Other surgery | Not reported | Not reported | 639 | 178 | 461 (N/A & 72.1%) |
| Faith investigators, 2018 | Other surgery | 7306 | 5609 | 1697 ^f | 589 | 1108 (15.2% & 65.3%) |
| HIP ATTACK investigators, 2020 | Other surgery | 27701 | 19921 | 7780 | 532 ^g | 2970 (10.7% & 38.2%) |
| Beard <i>et al.</i> , 2019 | Other surgery | 962 | 121 | 841 | 310 | 531 ^h (55.2% & 63.1%) |
| Beard <i>et al.</i> , 2018 | Placebo control/sham | 2975 | 2235 | 740 | 427 ⁱ | 313 (10.6% & 42.3%) |
| Paavola <i>et al.</i> , 2018 | Placebo control/sham | 281 | 68 | 213 | 3 | 210 (74.7% & 98.6%) |
| Firanesu <i>et al.</i> , 2018 | Placebo control/sham | 1280 | 944 | 336 | 156 | 180 (14.1% & 53.6%) |
| Clark <i>et al.</i> , 2016 | Placebo control/sham | 302 | 148 | 154 | 34 | 120 (39.7% & 77.9%) |

^a A further patient was not randomised as they incurred another injury following screening

^b A further 29 eligible patients were not invited to randomisation consultation

^c Three patients were randomised in error and did not receive treatment and were not followed-up

^d This is 24 eligible who declined all participation and 40 who declined randomisation but included in an observation cohort

^e Of the 127, 91 enrolled into a non-randomised cohort and 15 withdrew prior to randomisation and 21 did not wish to enrol at all/did not wish to have surgery or had surgery at another facility

^f The study reports that 1843 were eligible patients; however, of these 146 were potentially eligible but missed so were not confirmed as eligible patients

^g A further 4278 were eligible but not randomised for the following reasons: operating room board could not accommodate (n=1643), not identified before surgery (n=1009), surgeon not available (n=396), family did not consent (n=374), physician declined (n=231), other (n=625)

^h Of 531, three were randomised twice so excluded

ⁱ Of these 427, 232 took part in an observational cohort for patients with a strong preference and 195 did not partake in the trial or cohort

Description of key baseline characteristics

Tables 3S, 4S and 5S (refer to extended data) describe the key baseline characteristics of age, gender and ethnicity for (i) screened; (ii) ineligible; (iii) non-consenting; and (iv) randomised patients. Only two studies described the characteristics of both screened (age and gender only) and randomised patients^{43,46}, so heterogeneity was not statistically explored. The same two studies did this for ineligible patients and four studies for non-consenting patients^{17,36,43,46}. All 26 studies reported the age and gender of randomised patients and only four studies for ethnicity^{32,34,43,46}.

Inclusion of under-served populations

Table 6S (refer to extended data) describes the trial populations for characteristics relevant to under-served populations. There is considerable variation in the choice of lower age limit and ten of the 26 studies (39%) specified an upper age limit (for seven this was ≤ 75 years)^{24,25,28,29,32,33,36,39,42,44}. Four studies described the ethnicity of trial participants^{32,34,43,46}. Six studies described the education of the trial participants^{28,29,33,40,43,46}. Four of those studies, did not describe the entire sample, for example, only whether college education or equivalent was met^{28,29,33,40}. Eight studies reported the employment status of participants^{26,28,32,37,40,43,44,46}. No studies reported using deprivation scores to help recruit the target population, such as selecting a sample of recruiting sites to reflect a range of geographical populations that are historically under-served by

research activity. One study reported on place of residence (e.g. independent or nursing home)²³.

Methods to facilitate consent

Methods to facilitate consent are detailed in Table 7S (refer to extended data). One study reported that language barriers were addressed with the availability of translators⁴⁶. Two studies reported that study materials were available to potential participants in formats other than written, including the use of a DVD or verbal explanation^{38,40}. Most studies required written consent and completion of paper questionnaires. No studies reported the use of electronic or verbal consent and only three studies referred to electronic collection of questionnaires^{28,29,45}. Few studies mentioned whether patients without capacity to consent were included in their target population (n=7) or patients being excluded for this reason (n=15). Of the remaining four studies, consent was taken by, for example, a legal guardian or was a decision made by the clinical team in the context of the Mental Health Capacity Act 2005^{23,30,34,36}.

Pragmatic selection of trial participants

Table 2 summarises how pragmatic studies were in their selection of patients and includes questions about eligibility, recruitment and setting. For eligibility, 19 of the 26 studies (73%) were agreed to be 'very pragmatic' or 'rather pragmatic' in design, deeming trial participants similar to those patients in usual care. For recruitment, and the extra effort to do this beyond

Table 2. Pragmatic selection of patients into the included studies.

| Author (year) | Eligibility—To what extent are the participants in the trial similar to those who would receive this intervention if it was part of usual care? | Recruitment—How much extra effort is made to recruit participants over and above what would be used in the usual care setting to engage with patients? | Setting—How different are the settings of the trial from the usual care setting? |
|-----------------------------------|---|--|--|
| Ghogawala <i>et al.</i> , 2016 | Very explanatory | Rather explanatory | Rather explanatory |
| Försth <i>et al.</i> , 2016 | Rather pragmatic | Rather pragmatic | Rather pragmatic |
| Skou <i>et al.</i> , 2015 | Equally pragmatic and explanatory | Rather pragmatic | Rather explanatory |
| Bailey <i>et al.</i> , 2020 | Rather pragmatic | Rather pragmatic | Very explanatory |
| Willett <i>et al.</i> , 2016 | Rather pragmatic | Rather pragmatic | Very pragmatic |
| Ghogawala <i>et al.</i> , 2020 | Rather pragmatic | Rather pragmatic | Very pragmatic |
| Rangan <i>et al.</i> , 2015 | Very pragmatic | Very pragmatic | Very pragmatic |
| van de Graaf <i>et al.</i> , 2018 | Rather pragmatic | Rather pragmatic | Rather pragmatic |
| Rämö <i>et al.</i> , 2020 | Very explanatory | Rather pragmatic | Rather explanatory |
| Costa <i>et al.</i> , 2017 | Very pragmatic | Very pragmatic | Very pragmatic |
| Costa <i>et al.</i> , 2014 | Rather pragmatic | Very pragmatic | Very pragmatic |
| Costa <i>et al.</i> , 2022 | Rather pragmatic | Very pragmatic | Very pragmatic |
| Firanesu <i>et al.</i> , 2018 | Rather explanatory | Equally pragmatic and explanatory | Equally pragmatic and explanatory |
| Griffin <i>et al.</i> , 2014 | Very pragmatic | Very pragmatic | Equally pragmatic and explanatory |

| Author (year) | Eligibility—To what extent are the participants in the trial similar to those who would receive this intervention if it was part of usual care? | Recruitment—How much extra effort is made to recruit participants over and above what would be used in the usual care setting to engage with patients? | Setting—How different are the settings of the trial from the usual care setting? |
|--------------------------------|---|--|--|
| Kise <i>et al.</i> , 2016 | Rather explanatory | Rather pragmatic | Rather explanatory |
| Paavola <i>et al.</i> , 2018 | Rather explanatory | Rather pragmatic | Rather explanatory |
| Palmer <i>et al.</i> , 2019 | Equally pragmatic and explanatory | Rather pragmatic | Equally pragmatic and explanatory |
| Reijman <i>et al.</i> , 2021 | Rather pragmatic | Rather pragmatic | Rather pragmatic |
| Beard <i>et al.</i> , 2018 | Rather pragmatic | Very pragmatic | Very pragmatic |
| Faith investigators, 2018 | Very pragmatic | Very pragmatic | Very pragmatic |
| HIP ATTACK investigators, 2020 | Very pragmatic | Rather pragmatic | Very pragmatic |
| Dias <i>et al.</i> , 2020 | Very pragmatic | Very pragmatic | Very pragmatic |
| Beard <i>et al.</i> , 2019 | Very pragmatic | Very pragmatic | Very pragmatic |
| Griffin <i>et al.</i> , 2018 | Rather pragmatic | Rather pragmatic | Rather pragmatic |
| Rangan <i>et al.</i> , 2020 | Very pragmatic | Very pragmatic | Very pragmatic |
| Clark <i>et al.</i> , 2016 | Rather pragmatic | Rather pragmatic | Very explanatory |

how patients would be identified in usual care, 24 (92%) studies were ‘very pragmatic’ or ‘rather pragmatic’ in design. Then for the setting in which patients were recruited, 16 (62%) studies were ‘very pragmatic’ or ‘rather pragmatic’ in design.

Discussion

This review of orthopaedic surgical trials published in high impact journals illustrates considerable variation in how patients are recruited that could affect clinical applicability and acceptability of trial findings. There is marked variation in patients initially screened, who meet all the eligibility criteria, provide consent and are randomised into the study. Limited data were collected about key baseline characteristics of patients who pass through the different phases of patient selection. Notably only four studies (15%) reported on ethnicity which is similar to a recent review that found only 9.3% (38 of 407) of NIHR trials demonstrated exactly how they both recorded, and reported, ethnicity⁴⁸. Critical to understanding the selection of patients into RCTs is describing their enrolment in the flowchart of the CONSORT statement¹⁸. Most studies reported the different steps of enrolment but there is considerable selectivity of patients from the screened target population to who were randomised into the study. Within included studies we found limited data about ethnicity, education or employment status of patients. The methods did not explain how language barriers were addressed, and what alternative methods of data collection and enrolment of patients without capacity to consent were used. Studies were mostly pragmatic in recruitment of patients, which by definition should have clinical applicability. However, whilst judged to be pragmatic

in design²⁰, these findings suggest the need to think beyond what is traditionally considered to be pragmatic and truly be inclusive of all eligible patients and that of under-served populations.

Recently, a lack of patient representation in health care research has become the focus of the NIHR, the largest public funder of trials in the UK. Consequently, there has been an emphasis on including under-served groups. It is known, for example, that for musculoskeletal conditions some minority and ethnic groups are disproportionately represented because of risk factors such as levels of physical activity, vitamin D deficiency, poverty, and pre-existing long term conditions such as diabetes⁴⁹. A recent national survey from a representative sample of 5,030 people from across the UK found nine in ten people (88%) think a diverse mix of participants in health care and research is important even if the research costs more money (70%) or takes more time (74%)⁵⁰. Both leading funding bodies and the public expect to have inclusivity in research.

Sometimes trial teams may deliberately widen their screening to ensure every possible patient is considered for the study. Although there may be legitimate reasons for this, several included studies specified an upper age limit of ≤ 75 years which could proactively exclude eligible patients. When designing studies around the inclusive selection of patients and optimising the flow of patients careful consideration should be given to: defining the target population, the choice of eligibility criteria, who is involved in the screening of patients and the training they have and methods used to screen⁵¹, methods to minimise patient and/or surgeon preferences⁵² and optimise

patient recruitment⁵³ and involvement of patient and public collaborators⁵⁴.

Reporting key characteristics of patients who are screened, excluded because of eligibility criteria and who are not approached or do not consent may help reassure clinicians and policy makers about the representativeness of the trial sample. The General Data Protection Regulation in the UK provides the lawful basis for processing such data and the common law of confidentiality allows the collection of data without a legal basis as long as the patient cannot be identified⁵⁵. As an example, age could be collected in years (or age bands) or only the first part of a postcode to inform measures of deprivation. This allows the lawful and feasible collection of key characteristics of the screened population without the need for consent. A consistent approach from Research Ethics Committees/Health Research Authority and subsequent Information Governance professionals undertaking local site review is required as to what is acceptable to collect that ensures anonymity but permits reporting about inclusivity. This type of data capture may not be permissible, however, due to restrictions of different jurisdictions.

In the UK and the NIHR focus on improving inclusivity in research, frameworks are being or have been developed as to how this may be achieved^{7,8,56}. This is part of the NIHR work-stream called “Innovations in Clinical Trial Design and Delivery for the Under-served” (INCLUDE) project. This includes a roadmap that defines under-served groups and barriers to their inclusion⁸. The Ethnicity Framework launched on 1 October 2020 (<https://www.trialforge.org/trial-forge-centre/include/>) aims to help trial teams think about the inclusion of ethnic groups in their trial⁷. Multiple approaches to address the barriers to inclusive participation in research include: translation of recruitment and patient questionnaires subject to appropriate validation; and provision of materials in braille, audio-recorded, or animation and apps to help those with low literacy, learning or sensory difficulty. For these tools to be universally adopted into standard trial practice, a coordinated and consistent approach is required to their implementation with a greater understanding of their resource implications to be considerate of the workforce and pressures facing the NHS.

A strength of this review was applying the PRISMA guidelines^{14,15}. The protocol was registered prospectively. It was conducted by a multi-disciplinary team of methodologists, orthopaedic surgeons and trial coordinators. The review is limited to RCTs of orthopaedic surgical trials in high impact journals that are amongst the most cited medical journals and known to the authors as having published large-scale orthopaedic surgical trials. We chose to focus on these RCTs as they are likely to be the best resourced to deliver research and influence key stakeholders and clinical practice. The review team focussed on reporting what was presented in the main publication and supplementary material available on the journal website. It is possible that details not published by the journal are available in a full monograph, in trial registries or in the published protocol; although being described in a registry or protocol does not necessarily mean it was implemented. Moreover,

different journals may have different word count policies and what is permitted to be uploaded alongside an article. This review focused on the journal publication and supplementary material as that is most likely to be read by surgeons and to influence decisions in clinical practice. Several reviewers checked study inclusion and undertook data extraction that could contribute to variability in decision-making. This was to make the review feasible with the lack of resources to support it. Maintaining the standard of a second reviewer checking a first reviewer with recourse to always the same third reviewer should mitigate this limitation. Finally, identifying studies with simple search terms were undertaken of the journal website rather than an electronic database such as PUBMED as this was more feasible with the latter lacking specificity in the searches⁵⁷. Whilst this search strategy may not meet the standards of a systematic review of effectiveness we have nevertheless undertaken a comprehensive review with the resources available to us and makes an original and timely contribution to the literature.

Conclusion

Patient selection and recruitment is a key challenge for RCTs. Different clinical pathways and differences between participating sites and resources available add to the complexity of achieving this. However, the enrolment of a highly selective sample of patients may impact on the clinical applicability and acceptability of study findings. Trials often purport to be pragmatic in design. The limited data available about who and how patients are included in these studies, questions whether they truly are pragmatic and inclusive of the target population. This review is not a criticism of existing high impact orthopaedic surgical trials that are an important contribution to the evidence-base as only recently has there been this attention towards inclusivity and improving external validity. The challenge now is to address this and ensure every person eligible to take part has the same opportunity and are not excluded whether consciously or not. This is a requirement of leading funding bodies and an expectation of the public. This may be difficult and complex to implement as it requires time, resources and funding for which there can be an opportunity cost and needs to be integrated into efficient trial design and delivery⁵⁸. Change will also not happen on its own and needs initiatives that provide training and education on inclusivity in clinical trials⁵⁹ and practical guidance about how to implement strategies to achieve this⁶⁰. The NIHR is starting initiatives to provide training in inclusive research design⁶¹ and regulatory bodies are developing guidance on increasing diversity of people taking part in clinical trials⁶². The promotion of decentralised clinical trials away from trial sites could also improve inclusivity in recruitment allowing participants to overcome geographical, financial, family and work constraints⁶³.

Finally, the following practical guidance could improve inclusivity in the screening and recruitment of patients into orthopaedic surgical trials:

(i) screening and eligibility criteria – including collection of data to allow complete reporting of the CONSORT flowchart¹⁸, careful consideration in the definition of eligibility criteria⁶⁴, and

efficient data capture methods to record data on those patients screened, eligible, approached and randomised⁵¹.

(ii) collection and reporting on attributes to ensure no section of the eligible population is inadvertently excluded – including, for example, collecting data during screening on age, sex, ethnicity and (first part of) postcode to inform measures of deprivation which are often not reported yet known to influence patient outcomes^{4,65,66}.

(iii) embedding mechanisms to allow all eligible patients the opportunity to participate – including making information accessible in a variety of formats such as the translation of recruitment materials; provision of materials in braille, audio-recorded, or animation (that allows captions in different languages); and direction to apps to help read printed materials.

Ethics and consent

This study did not require any form of ethical approval or consent

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Extended data

Figshare: Supporting materials for review of high impact journals about inclusivity in orthopaedic surgical randomised trials

An additional file including Tables 1S to 7S of extended data is available at Figshare repository along with the trial protocol and PRISMA checklist (<https://doi.org/10.6084/m9.figshare.27074599>)⁶⁷.

This project contains the following underlying data:

- Tables 1S to 7S extended data
- Applicability of orthopaedic surgical trials review protocol_2023.02.02.docx

Reporting guidelines

Figshare: PRISMA checklist for “Inclusivity of the target population in orthopaedic surgical randomised trials: a review of high impact journals”. Doi: <https://doi.org/10.6084/m9.figshare.27074599>⁶⁷

This data is available under the terms of the Creative Commons Zero “No rights reserved” data waiver.

Author contributions

CRediT author statement: All authors contributed to conceptualization, visualization, methodology, writing – original draft, writing – review and editing. SB, LA, CK, EC, KH, JN, NAJ and JJD also contributed to data curation, investigation and validation.

Acknowledgements

There are no acknowledgements as this review was solely undertaken by the authors.

References

1. Cook JA: **The challenges faced in the design, conduct and analysis of surgical Randomised Controlled Trials.** *Trials.* 2009; **10**: 9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Hanzlik S, Mahabir RC, Baynosa RC, *et al.*: **Levels of evidence in research published in *The Journal of Bone and Joint Surgery* (American volume) over the last thirty years.** *J Bone Joint Surg Am.* 2009; **91**(2): 425–8. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Knowlson C, Dean A, Doherty L, *et al.*: **Recruitment patterns in multicentre randomised trials fit more closely to price's law than the Pareto principle: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme.** *Contemp Clin Trials.* 2022; **113**: 106665. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Rothwell PM: **External validity of Randomised Controlled Trials: “to whom do the results of this trial apply?”.** *Lancet.* 2005; **365**(9453): 82–93. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Hopewell S, Hirst A, Collins GS, *et al.*: **Reporting of participant flow diagrams in published reports of randomized trials.** *Trials.* 2011; **12**: 253. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Toerien M, Brookes ST, Metcalfe C, *et al.*: **A review of reporting of participant recruitment and retention in RCTs in six major journals.** *Trials.* 2009; **10**: 52. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Treweek S, Banister K, Bower P, *et al.*: **Developing the INCLUDE ethnicity framework—a tool to help trialists design trials that better reflect the communities they serve.** *Trials.* 2021; **22**(1): 337. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Witham MD, Anderson E, Carroll C, *et al.*: **Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process.** *Trials.* 2020; **21**(1): 694. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Blencowe NS, Cook JA, Pinkney T, *et al.*: **Delivering successful randomized controlled trials in surgery: methods to optimize collaboration and study design.** *Clin Trials.* 2017; **14**(2): 211–8. [PubMed Abstract](#) | [Publisher Full Text](#)
10. Sterne JAC, Savović J, Page MJ, *et al.*: **RoB 2: a revised tool for assessing risk of bias in randomised trials.** *BMJ.* 2019; **366**: 14869. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Fullilove S, Gozzard C: **Dorsally displaced fractures of the distal radius: a critical appraisal of the DRAFFT (Distal Radius Acute Fracture Fixation Trial) study.** *Bone Joint J.* 2016; **98-B**(3): 298–300. [PubMed Abstract](#) | [Publisher Full Text](#)
12. Nwachukwu BU, Kahlenberg CA, Lehman JD, *et al.*: **Characteristics of orthopedic publications in high-impact general medical journals.** *Orthopaedics.* 2017; **40**(3): e405–e12. [PubMed Abstract](#) | [Publisher Full Text](#)
13. Schmidtko KA, Evison F, Grove A, *et al.*: **Surgical implementation gap: an interrupted time series analysis with interviews examining the impact of surgical trials on surgical practice in England.** *BMJ Qual Saf.* 2023; **32**(6): 341–56. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Shamseer L, Moher D, Clarke M, *et al.*: **Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) 2015: elaboration and explanation.** *BMJ.* 2015; **350**: g7647. [PubMed Abstract](#) | [Publisher Full Text](#)
15. Moher D, Liberati A, Tetzlaff J, *et al.*: **Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA statement.** *PLoS Med.* 2009; **6**(7): e1000097. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Wartolowska K, Judge A, Hopewell S, *et al.*: **Use of placebo controls in the evaluation of surgery: systematic review.** *BMJ.* 2014; **348**: g3253. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Costa ML, Achten J, Parsons NR, *et al.*: **Percutaneous fixation with Kirschner wires versus volar locking plate fixation in adults with dorsally displaced**

- fracture of distal radius: Randomised Controlled Trial. *BMJ*. 2014; **349**: g4807.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Moher D, Hopewell S, Schulz KF, *et al.*: **CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.** *BMJ*. 2010; **340**: c869.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 19. NIHR: **Improving inclusion of under-served groups in clinical research: guidance from INCLUDE project.** 2020; [Accessed date 18 January 2022].
[Reference Source](#)
 20. Loudon K, Treweek S, Sullivan F, *et al.*: **The PRECIS-2 tool: designing trials that are fit for purpose.** *BMJ*. 2015; **350**: h2147.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Hicks A, Fairhurst C, Torgerson DJ: **A simple technique investigating baseline heterogeneity helped to eliminate potential bias in meta-analyses.** *J Clin Epidemiol*. 2018; **95**: 55–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Prestmo A, Hagen G, Sletvold O, *et al.*: **Comprehensive geriatric care for patients with hip fractures: a prospective, randomised, controlled trial.** *Lancet*. 2015; **385**(9978): 1623–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. HIP ATTACK Investigators: **Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.** *Lancet*. 2020; **395**(10225): 698–708.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Palmer AJR, Ayyar Gupta V, Fernquest S, *et al.*: **Arthroscopic hip surgery compared with physiotherapy and activity modification for the treatment of symptomatic Femoroacetabular Impingement: multicentre Randomised Controlled Trial.** *BMJ*. 2019; **364**: l185.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. Beard DJ, Rees JL, Cook JA, *et al.*: **Arthroscopic Subacromial Decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial.** *Lancet*. 2018; **391**(10118): 329–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Beard DJ, Davies LJ, Cook JA, *et al.*: **The clinical and cost-effectiveness of total versus Partial Knee Replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a Randomised Controlled Trial.** *Lancet*. 2019; **394**(10200): 746–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Willett K, Keene DJ, Mistry D, *et al.*: **Close contact casting vs surgery for initial treatment of unstable ankle fractures in older adults: a Randomised Clinical Trial.** *JAMA*. 2016; **316**(14): 1455–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Reijman M, Eggerding V, Van Es E, *et al.*: **Early surgical reconstruction versus rehabilitation with elective delayed reconstruction for patients with Anterior Cruciate Ligament rupture: COMPARE Randomised Controlled Trial.** *BMJ*. 2021; **372**: n375.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. van de Graaf VA, Noordduyn JCA, Willigenburg NW, *et al.*: **Effect of early surgery vs Physical Therapy on knee function among patients with nonobstructive meniscal tears: the ESCAPE Randomized Clinical Trial.** *JAMA*. 2018; **320**(13): 1328–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 30. Costa ML, Achten J, Griffin J, *et al.*: **Effect of locking plate fixation vs intramedullary nail fixation on 6-month disability among adults with displaced fracture of the distal tibia: the UK FixDT Randomized Clinical Trial.** *JAMA*. 2017; **318**(18): 1767–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 31. Rämö L, Sumrein BO, Lepola V, *et al.*: **Effect of surgery vs functional bracing on functional outcome among patients with closed displaced humeral shaft fractures: the FISH Randomized Clinical Trial.** *JAMA*. 2020; **323**(18): 1792–801.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Ghogawala Z, Terrin N, Dunbar MR, *et al.*: **Effect of ventral vs dorsal spinal surgery on patient-reported physical functioning in patients with cervical spondylotic myelopathy: a Randomized Clinical Trial.** *JAMA*. 2021; **325**(10): 942–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 33. Kise NJ, Risberg MA, Stensrud S, *et al.*: **Exercise therapy versus Arthroscopic Partial Meniscectomy for degenerative meniscal tear in middle aged patients: Randomised Controlled Trial with two year follow-up.** *Br J Sports Med*. 2016; **50**(23): 1473–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) Investigators: **Fracture fixation in the operative management of hip fractures (FAITH): an international, multicentre, Randomised Controlled Trial.** *Lancet*. 2017; **389**(10078): 1519–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 35. Griffin DR, Dickenson EJ, Wall PDH, *et al.*: **Hip arthroscopy versus best conservative care for the treatment of Femoroacetabular Impingement syndrome (UK FASHIoN): a multicentre Randomised Controlled Trial.** *Lancet*. 2018; **391**(10136): 2225–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Ghogawala Z, Dziura J, Butler WE, *et al.*: **Laminectomy plus fusion versus laminectomy alone for lumbar spondylolisthesis.** *N Engl J Med*. 2016; **374**(15): 1424–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Rangan A, Brealey SD, Keding A, *et al.*: **Management of adults with primary frozen shoulder in secondary care (UK FROST): a multicentre, pragmatic, three-arm, superiority randomised clinical trial.** *Lancet*. 2020; **396**(10256): 977–89.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Griffin D, Parsons N, Shaw E, *et al.*: **Operative versus non-operative treatment for closed, displaced, intra-articular fractures of the calcaneus: Randomised Controlled Trial.** *BMJ*. 2014; **349**: g4483.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 39. Försth P, Ólafsson G, Carlsson T, *et al.*: **A randomized, controlled trial of fusion surgery for lumbar spinal stenosis.** *N Engl J Med*. 2016; **374**(15): 1413–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Skou ST, Roos EM, Laursen MB, *et al.*: **A randomized, controlled trial of total knee replacement.** *N Engl J Med*. 2015; **373**(17): 1597–606.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Clark W, Bird P, Gonski P, *et al.*: **Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial.** *Lancet*. 2016; **388**(10052): 1408–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Paavola M, Malmivaara A, Taimela S, *et al.*: **Subacromial decompression versus diagnostic arthroscopy for shoulder impingement: randomised, placebo surgery controlled clinical trial.** *BMJ*. 2018; **362**: k2860.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Dias JJ, Brealey SD, Fairhurst C, *et al.*: **Surgery versus cast immobilisation for adults with a bicortical fracture of the scaphoid waist (SWIFT): a pragmatic, multicentre, open-label, randomised superiority trial.** *Lancet*. 2020; **396**(10248): 390–401.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Bailey CS, Rasoulinejad P, Taylor D, *et al.*: **Surgery versus conservative care for persistent sciatica lasting 4 to 12 months.** *N Engl J Med*. 2020; **382**(12): 1093–102.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Costa ML, Achten J, Ooms A, *et al.*: **Surgical fixation with K-wires versus casting in adults with fracture of distal radius: DRAFFT2 multicentre randomised clinical trial.** *BMJ*. 2022; **376**: e068041.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Rangan A, Handoll H, Brealey S, *et al.*: **Surgical vs nonsurgical treatment of adults with displaced fractures of the proximal humerus: the PROFHER randomized clinical trial.** *JAMA*. 2015; **313**(10): 1037–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Firanescu CE, De Vries J, Lodder P, *et al.*: **Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial.** *BMJ*. 2018; **361**(361): k1551.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Wallace N, O’Keeffe S, Gardner H, *et al.*: **Underreporting and underreporting of participant ethnicity in clinical trials is persistent and is a threat to inclusivity and generalizability.** *J Clin Epidemiol*. 2023; **162**: 81–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Jeraj S, Butt J: **Musculoskeletal conditions and Black, Asian and minority ethnic people: addressing health inequalities.** Race Equality Foundation; 2020.
[Reference Source](#)
 50. Health Research Authority: **Public perceptions of research.** 2023; [updated 21 Nov 2023].
[Reference Source](#)
 51. Wilson C, Rooshenas L, Paramasivan S, *et al.*: **Development of a framework to improve the process of recruitment to Randomised Controlled Trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework.** *Trials*. 2018; **19**(1): 50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 52. Davies L, Beard D, Cook JA, *et al.*: **The challenge of equipoise in trials with a surgical and non-surgical comparison: a qualitative synthesis using meta-ethnography.** *Trials*. 2021; **22**(1): 678.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. Scantlebury A, McDaid C, Brealey S, *et al.*: **Embedding qualitative research in Randomised Controlled Trials to improve recruitment: findings from two recruitment optimisation studies of orthopaedic surgical trials.** *Trials*. 2021; **22**(1): 461.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 54. Crocker JC, Ricci-Cabello I, Parker A, *et al.*: **Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis.** *BMJ*. 2018; **363**: k4738.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 55. Health Research Authority: **Types of health and care information and the legal frameworks protecting them.** 2022; [updated 5 Dec 2022].
[Reference Source](#)
 56. Shepherd V, Joyce K, Flynn S, *et al.*: **INCLUDE impaired capacity to consent framework.** 2022; [Accessed date 12 July 2023].
[Reference Source](#)
 57. Hopewell S, Clarke M, Lefebvre C, *et al.*: **Handsearching versus electronic**

- searching to identify reports of randomized trials. *Cochrane Database Syst Rev.* 2007; **2007**(2): MR000001.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. NIHR: **Best research for best health: the next chapter**. National Institute of Health Research, 2021.
[Reference Source](#)
59. Shiely F, Rychlíčková J, Kubiak C, *et al.*: **Training and education on inclusivity in clinical trials—the SENSITISE project**. *Trials.* 2024; **25**(1): 318.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Biggs K, Hullock K, Dix C, *et al.*: **Time to STEP UP: methods and findings from the development of guidance to help researchers design inclusive clinical trials**. *BMC Med Res Methodol.* 2024; **24**(1): 227.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. NIHR: **Inclusive research design to become an NIHR condition of funding**. [Accessed date 16 October 2024].
[Reference Source](#)
62. Health Research Authority: **HRA and MHRA draft inclusion and diversity guidance**. [Accessed date 16 October 2024].
[Reference Source](#)
63. Vayena E, Blasimme A, Sugarman J: **Decentralised clinical trials: ethical opportunities and challenges**. *Lancet Digit Health.* 2023; **5**(6): e390–e4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Dawson S, Banister K, Biggs K, *et al.*: **Trial forge guidance 3: randomised trials and how to recruit and retain individuals from ethnic minority groups—practical guidance to support better practice**. *Trials.* 2022; **23**(1): 672.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Averbuch T, Mohamed MO, Islam S, *et al.*: **The association between Socioeconomic Status, sex, race / ethnicity and in-hospital mortality among patients hospitalized for heart failure**. *J Card Fail.* 2022; **28**(5): 697–709.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Cheng AL, Bradley EC, Brady BK, *et al.*: **The influence of race, sex, and social disadvantage on self-reported health in patients presenting with chronic musculoskeletal pain**. *Am J Phy Med Rehabil.* 2022; **101**(3): 211–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Brealey S: **Supporting materials for review of high impact journals about inclusivity in orthopaedic surgical randomised trials**. *figshare.* 2024; [cited 2025 Jan 6].
https://figshare.com/articles/journal_contribution/Detailed_description_of_the_eligibility_criteria_and_patient_population/27074599/3

Open Peer Review

Current Peer Review Status: ? ✖

Version 1

Reviewer Report 03 March 2025

<https://doi.org/10.3310/nihropenres.14969.r34610>

© 2025 Madden K. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Kim Madden 

¹ McMaster University, Hamilton, Ontario, Canada

² McMaster University, Hamilton, Ontario, Canada

Thank you for the opportunity to review this paper. Inclusivity is a key issue in orthopaedics and the topic is very important. However, I have several comments about the paper.

1. Several studies have been missed. There are more than 26 orthopaedic trials in major journals in the past decade. E.g. [Ref 1] [Ref 2].

The search strategy is flawed because the exact term "randomized" is not always used. Sometimes it is "randomly assigned" or "randomization" as in the examples given here.

2. This type of analysis that involves describing the excluded sample is challenging because each site or local ethics committee will have different requirements/processes for screening and recording who was screened. Our site is not allowed to keep any data on patients who do not consent. Researchers in my jurisdiction are not even allowed to know about patients who declined to be screened or declined to talk to research staff so those are never reported. I have noticed vastly different numbers of patients screened at different sites, not because of different actual numbers of patients, but different screening processes and privacy laws.

3. Why use a fixed effects model? Random effects seems more appropriate here.

4. "One study reported including participants living at an alternative place of residence, that is a nursing home [cites the HIP ATTACK trial]". The HIP ATTACK trial didn't recruit from nursing homes, it included patients presenting to level 1 trauma centres from anywhere, including nursing homes. Many hip fracture trials would do the same. This is a bit misleading and could be worded better. Something like "one study reported on place of residence (e.g. independent or nursing home)".

References

1. HEALTH Investigators, Bhandari M, Einhorn TA, Guyatt G, et al.: Total Hip Arthroplasty or Hemiarthroplasty for Hip Fracture. *N Engl J Med*. 2019; **381** (23): 2199-2208 [PubMed Abstract](#) | [Publisher Full Text](#)

2. FLOW Investigators, Bhandari M, Jeray KJ, Petrisor BA, et al.: A Trial of Wound Irrigation in the Initial Management of Open Fracture Wounds. *N Engl J Med*. 2015; **373** (27): 2629-41 [PubMed](#)

[Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: research methodology, clinical trials, systematic reviews, orthopaedic trauma, arthroplasty

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 31 Mar 2025

Stephen Brealey

Thank you for your comments on our article.

1. We comment in the last paragraph of the Discussion that it was more feasible to search by journal and we adapted the terms we used specific to the journal being searched.

2. We comment in the fourth paragraph of the Discussion that a consistent approach is required by committees to allow collection of these data and what is agreed locally by IG professionals. We have added an extra sentence to this paragraph to recognise your important point about how this data capture may be limited by different jurisdictions.

3. The planned meta-analysis to explore heterogeneity in baseline characteristics (i.e. age, gender, ethnicity) between patients screened but not randomised and those randomised was not ultimately feasible as there were too few studies. This analysis was planned to explore the assumption that if the trials were truly inclusive then the participants randomised would be a representative sample of those screened, and as such there should

be no difference between the baseline characteristics of these two groups, rather like if they had been formed by random allocation. Therefore, a fixed effects meta-analysis was planned rather than a random effects on the assumption that there was a common treatment estimate (i.e. zero) for the baseline characteristics between these two groups across the trials and the only legitimate source of between study variation is due to chance, which is accounted for in a fixed effects model. Whereas a random effects model assumes and allows for heterogeneity i.e. in this case that the difference between the baseline characteristics of the two groups would vary across the different trials. Following the fixed effects meta-analysis, we would have interpreted the resulting I^2 value of heterogeneity in line with the Cochrane handbook guidelines (i.e. 0%–40% might not be important; 30%–60% may represent moderate heterogeneity; 50%–90% may represent substantial heterogeneity; and 75%–100% considerable heterogeneity).

Ref. Hicks A, Fairhurst C, Torgerson DJ. A simple technique investigating baseline heterogeneity helped to eliminate potential bias in meta-analyses. *J Clin Epidemiol*. 2018;95:55-62.

4. Thank you, we have modified the sentence as suggested.

We understand your concerns about potentially missing some studies, however, our aim was not to undertake a systematic review like that for effectiveness. For the reasons given, we purposefully focused on high impact journals and to keep it feasible with no funding. We have undertaken a comprehensive review and used the PRISMA principles where appropriate to bring rigour to its design and conduct. Inclusivity is an important topic and our take home message is that, even among the highest quality journals, it is difficult for surgeons to make an assessment of whether a trial population is representative of their clinical population. We think this is an important message that would not have been impacted by the methods selected. Therefore, in our opinion, this remains an original and timely contribution to the literature.

Competing Interests: None.

Reviewer Report 18 February 2025

<https://doi.org/10.3310/nihropenres.14969.r34609>

© 2025 Retzer A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Ameeta Retzer

¹ University of Birmingham, Birmingham, England, UK

² University of Birmingham, Birmingham, England, UK

1. This article describes a review of randomised controlled trials in orthopaedic surgery and whether they are inclusive of their target populations, including under-served groups. This is a timely and interesting study of research inclusion in orthopaedic surgery.

2. The article is clearly presented and appears to cite the appropriate literature.

3. Study design and description of methods - I am not familiar with the methods used to identify the literature through searching journal databases. In the discussion, Hopewell et al are cited for their study on using handsearching versus electronic searching to identify RCT reports to justify use of this method over the use of electronic databases. This reference is from 2007 and I am not sure if this justification still stands as the usual practice to systematically identify literature. While the journals searched are high-impact, it is not clear on what basis these were chosen and it may be that surgery-specific journals or orthopaedics journals would have been more appropriate. I am also not familiar with how journals index their articles so not clear on whether the terms used were appropriate. I would suggest expanding on this in the limitations section of the paper as the methods as they are currently described and justified do not assure that this was the most systematic way to identify the relevant literature to address this research question. Further due to the variation in journalistic styles of each of the journals, there is likely to be variation in the volume of detail in each of the articles e.g one journal may have a more restrictive wordcount than another or a policy of sharing the protocol as a supplementary appendix may have been introduced at a different time. As such, the comparison between two articles from different journals may not be like with like nor would they necessarily yield the necessary information to answer the research question.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Not applicable

Are all the source data underlying the results available to ensure full reproducibility?

No source data required

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: - systematic evaluation of clinical trial protocols and reports, inclusive and equitable research design. I am not an expert in surgical or orthopaedic research.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 31 Mar 2025

Stephen Brealey

Thank you for your comments on our article. We agree that the method of handsearching has limitations, however, this is not a systematic review like would be done to assess effectiveness, and the focus on specific journals meant we chose to search them directly. The final paragraph of the Introduction and the Discussion explains why we focus on high impact journals rather than surgery-specific journals i.e. these trials are most likely to inform surgical practice and to be the most resourced to address all the aspects of inclusivity of the target population. We chose the specific journals as they are amongst the most cited medical journals and to the authors of this review, they are journals known to have published large scale surgical trials that are likely to influence practice. Similarly, we acknowledge in the last paragraph of the Discussion why we focused on the journal article and Supplementary material, again this is what is likely to be read by surgeons to inform their practice. Journals will have different policies about word count and the extent to which material is available; this, however, is what surgeons access to inform decision-making. We have elaborated a little further on these points in the final paragraph of the Discussion.

Essentially, we were trying to provide a 'snapshot' of what could be considered best practice in trial publication, in order to highlight issues relating to inclusivity. We do not expect that wider inclusion criteria would have changed the findings from this review. What we have learned is that, based on trials published in, arguably, the most prestigious and influential journals, it is difficult for clinicians to assess whether the characteristics of those participating in the trial reflects the demographics of the patient population. We think this is an important finding to make known to the research community.

Competing Interests: None.